MiNK Therapeutics(US:INKT)2025-05-15 11:30Financial Performance - MiNK Therapeutics reported a cash balance of $3.2 million at the end of Q1 2025, down from $4.6 million at the end of Q4 2024[10] - Cash used in operations for Q1 2025 was $1.3 million, a decrease of 48% compared to $2.5 million in Q1 2024[8] - The net loss for Q1 2025 was $2.8 million, or $0.70 per share, compared to a net loss of $3.8 million, or $1.10 per share, in Q1 2024[8] - Research and development expenses decreased to $1.3 million in Q1 2025 from $2.6 million in Q1 2024, reflecting a reduction of 50%[14] Clinical Development - MiNK is actively enrolling patients in a Phase 2 trial for gastric cancer, with new data showing promising results in PD-1–resistant tumors[6] - The company is pursuing broader patient access through clinical trials and compassionate use programs for its iNKT therapy in ARDS[6] - A peer-reviewed publication is expected in the first half of 2025 detailing a complete remission case in a patient with metastatic testicular cancer treated with agenT-797[6] Strategic Initiatives - MiNK has been selected for probable funding by NIAID to support its allogeneic iNKT program in GvHD, with a formal award expected by June 2025[6] - The company is engaged in advanced discussions for strategic partnerships in oncology, immune-mediated diseases, and next-generation engineered cell therapies[3] - MiNK's iNKT platform is positioned to deliver off-the-shelf therapies to patients with urgency, focus, and scale, leveraging clinical advances and expanded access to non-dilutive capital[2]